AXS-12 for the Treatment of Narcolepsy: Topline Results from the Phase 3 SYMPHONY Trial (PL5.007)
SYMPHONY, a Phase 3, randomized, double-blind, placebo-controlled trial, assessed the efficacy and safety of AXS-12 (reboxetine) in narcolepsy type 1 (NT1).
Authors
- Lois E. Krahn
- Eileen Leary (ORCID: https://orcid.org/0000-0002-7389-6384)
- Herriot Tabuteau
- Bruce Corser
- Angad Chhabra
- Richard Bogan (ORCID: https://orcid.org/0000-0001-7043-2974)
- Colin M. Shapiro (ORCID: https://orcid.org/0000-0002-2231-0427)
- Michael J. Thorpy
Institutions
- Montefiore Medical Center (US)
- Toronto Western Hospital (CA)
- WinnMed (US)
- Axsome Therapeutics (United States) (US)
- SleepMed (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208585
- Primary Topic
- Sleep and Wakefulness Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00